HOME >> MEDICINE >> NEWS
Acrux and Oreganon further expand their collaboration

Drug delivery company Acrux (ASX: ACR), announced today that it has signed a further agreement with Organon, the human healthcare business unit of Akzo Nobel, expanding the two parties' collaboration. This follows the recently announced deal under which Organon and Acrux will develop and commercialise contraceptives, delivered through the skin using Acrux's unique spray technology.

Under the new agreement, Organon has licensed Acrux's technology for delivery of a non-hormone, proprietary Organon drug, for a substantial global women's health market.

"The expansion of our important relationship with Organon, one of the leading innovators in women's health, confirms that our unique spray technology has even broader potential" said Acrux CEO Richard Treagus.

"This adds a new, non-hormone drug to our pipeline and demonstrates the potential to use the technology to deliver drugs owned by our partners", he added.

Organon executive vice president, Research and Development, David Nicholson commented "The Acrux technology is an appealing method of delivering medication, with the potential to extend the choices available for women to fit their needs and lifestyle."

Acrux will be responsible for developing formulations of the undisclosed compound and upon successful completion; Organon will undertake and fund all clinical trials, regulatory submissions, manufacturing and commercialization efforts.

Acrux may receive payments totalling US$12 million as development and regulatory milestones are achieved.

Acrux will also earn royalties on worldwide sales of the product.


'"/>

Contact: Richard Treagus
richard.treagus@acrux.com.au
61-383-790-100
Research Australia
6-Mar-2007


Page: 1

Related medicine news :

1. Acrux completes enrollment in key phase 2 trial
2. Acrux granted first grant in Europe, triggering payment from Lilly
3. Acrux patent portfolio advances in USA
4. Acrux acquires rights to commercialise worlds first contraceptive spray
5. Four new us patents granted to Acrux for transdermal drug delivery
6. Acrux reports progress in development of Testosterone MD-Lotion(R) for men
7. Stomach cancer rate set to fall further 25 percent over next decade
8. High tech help to prevent further heart disease
9. Altered activity in receptor pair points to further complexity in schizophrenia pathology
10. Mount Sinai and YAI/NIPD Network join forces to further quality of care for people with autism
11. Data further examines Seroquel (quetiapine fumarate) treatment for bipolar depression

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/6/2016)... ... 2016 , ... Of the variety of ingredients in the food supply, few ... to common beliefs that hot dogs include “everything but the oink,” today’s wieners are ... combined with meat and poultry in a hot dog recipe can add flavor, keep ...
(Date:12/6/2016)... ... 06, 2016 , ... The NALA, a boutique marketing agency, is proud to ... (TBCF), a nonprofit 501(C)(3) organization providing financial and emotional support to families of children ... TBCF, the NALA recently hosted a Thanksgiving food drive that resulted in four boxes ...
(Date:12/6/2016)... ... December 06, 2016 , ... The Behavioral Health Center of ... the organization as a top behavioral service provider in the country. The award ... staff satisfaction and qualifications, and consumer satisfaction. These areas are measured via a ...
(Date:12/6/2016)... ... December 06, 2016 , ... Experimentation ... research and development, largely due to its potential for revolutionizing human disease treatment. ... and human induced pluripotent stem cells (hiPSCs). , Both platforms have distinct ...
(Date:12/6/2016)... Switzerland (PRWEB) , ... December 06, 2016 , ... ... a one-stop portal for all the knowledge resources, including white papers, guides, ... certificates, and more. , To access more than 9,000 documents, webinars and ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec. 5, 2016 Spain Glaucoma ... GlobalData,s new report, "Spain Glaucoma Surgery Devices Market Outlook ... Glaucoma Surgery Devices market. The report provides value, in ... prices (USD) within market segements - Canaloplasty Micro Catheters ... company shares and distribution shares data for each of ...
(Date:12/5/2016)... YORK , Dec. 5, 2016 ... penicillin in 1948, antibiotics have emerged as a ... several infectious conditions. In addition, antibiotics are also ... undergone surgery, or immunocompromised patients (cancer patients undergoing ... in healthcare and food production, has rapidly accelerated ...
(Date:12/5/2016)... 2016  Parallax Health Sciences, Inc. ("Parallax" or the ... its pharmaceutical business, RoxSan Pharmacy, Inc. has received a ... all of the 42 states it is currently licensed ... Rashti Pharm . D, Pharmacist in Charge at RoxSan ... business. Medicare B spending last year came to roughly ...
Breaking Medicine Technology:
Cached News: